Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Trial Description

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with surgery may kill more tumor cells.

PURPOSE: This phase II trial is studying how well irinotecan and cisplatin followed by surgery, floxuridine, and cisplatin work in treating patients with stomach cancer.

Further Study Information

OBJECTIVES:

• Determine the complete and partial response rates and time to treatment failure in patients with advanced gastric cancer treated with neoadjuvant irinotecan and cisplatin followed by surgery then intraperitoneal floxuridine and cisplatin.

• Determine the rate of potentially curative surgery in patients receiving this regimen.

• Determine the toxicity and tolerance of this regimen in these patients.

OUTLINE: Patients receive cisplatin IV and irinotecan IV once a week for 4 weeks. This course is repeated 2 weeks later.

Patients who achieve complete or partial remission or stable disease undergo resection 4 weeks after the last chemotherapy dose.

Patients with no residual macroscopic disease begin adjuvant intraperitoneal (IP) chemotherapy 1 week after surgery. Chemotherapy consists of floxuridine IP over 30 minutes on days 1-3 and days 22-24 and cisplatin IP on days 3 and 24.

PROJECTED ACCRUAL: A total of 18-33 patients will be accrued for this study within 2 years.

Eligibility Criteria

DISEASE CHARACTERISTICS:

• Histologically proven, previously untreated gastric cancer

• Stage IB, II, III, or IV (T3-4, N0 OR any T, N1-2, M0)

• No metastases

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• SWOG 0-2

Life expectancy:

• Not specified

Hematopoietic:

• WBC at least 4000/mm^3

• Platelet count at least 100,000/mm^3

• Hemoglobin at least 9 g/dL

Hepatic:

• Bilirubin less than 2 mg/dL

• SGOT/SGPT no greater than 2 times upper limit of normal (ULN)

• Alkaline phosphatase no greater than 3 times ULN

• PT, aPTT, and TT normal

• No Gilbert's disease

Renal:

• BUN no greater than 30 mg/dL

• Creatinine no greater than 1.5 mg/dL OR

• Creatinine clearance greater than 60 mL/min

Cardiovascular:

• No myocardial infarction within the past 3 months

• No congestive heart failure requiring therapy

Other:

• No other invasive malignancy in the past 5 years except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix

• No active or uncontrolled infection

• HIV negative

• No other severe concurrent disease

• No psychiatric disorders that would preclude compliance

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• No prior chemotherapy for gastric cancer

Endocrine therapy:

• Not specified

Radiotherapy:

• No prior radiotherapy for gastric cancer

Surgery:

• No prior surgery for gastric cancer

• No emergent need for surgery for gastrointestinal obstruction, perforation, or hemorrhage

Trial Contact Information

Trial Lead Organizations/Sponsors

NYU Cancer Institute at New York University Medical Center

Elliot Newman, MD

Study Chair

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00004103
Information obtained from ClinicalTrials.gov on December 14, 2011

Back to Top